Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

HIS medical history - prostate prostate cancer - HIS

- 13/04/2021 - 1 Formulário, 7 Grupos de itens, 39 Elementos de dados, 2 Idiomas

Grupos de itens: Admininstrative Daten, Organspezifisch Prostata, Gewebebanking Einwilligung, Tumorspezifische Daten, Patientenbefragung, Score, EORTC Fragen

HIS form from Soarian. Urologie Erlangen" with friendly permission of the urology Erlangen (Prof. Wullich) and the medical informatics department Erlangen (PD Dr. Bürkle)

Neurological History Cardiovascular Health Study (CHS)

- 13/04/2021 - 1 Formulário, 9 Grupos de itens, 191 Elementos de dados, 1 Idioma

Grupos de itens: Stroke, TIA, Sudden loss or change of speech, Sudden loss of vision, Double vision, Sudden numbness or tingling, Sudden paralysis or weakness, Dizziness or loss of balance, Date of interview

Documentation part: Record 22 Neurological History The Cardiovascular Health Study (CHS) was initiated by the National Heart, Lung and Blood Institute (NHLBI) in 1987 to determine the risk factors for development and progression of cardiovascular disease (CVD) in older adults, with an emphasis on subclinical measures. The study recruited 5,888 adults aged 65 or older at entry in four U.S. communities and conducted extensive annual clinical exams between 1989-1999 along with semi-annual phone calls, events adjudication, and subsequent data analyses and publications. Additional data were collected by studies ancillary to CHS. With the exception of annual clinic visits, these activities are still ongoing. Data obtained from: https://chs-nhlbi.org/ Permission granted by: Erika Enright.

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Module 1 - Screening (Demography; Vital Signs; History of Small Cell Lung Cancer; Previous Radiotherapy for Small Cell Lung Cancer; Previous Radiotherapy for Small Cell Lung Cancer

- 08/04/2021 - 1 Formulário, 8 Grupos de itens, 29 Elementos de dados, 1 Idioma

Grupos de itens: Administrative, Demography, Vital Signs, History of Small Cell Lung Cancer, Previous Surgical Procedures for Small Cell Lung Cancer, Previous Surgical Procedures for Small Cell Lung Cancer , Previous Radiotherapy for Small Cell Lung Cancer, Previous Radiotherapy for Small Cell Lung Cancer

lung Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Patient Enrollment/ Patient Eligibility - Demographics; General Medical History; Prior Therapy; History of Lymphoma

- 18/03/2021 - 1 Formulário, 13 Grupos de itens, 46 Elementos de dados, 1 Idioma

Grupos de itens: Administrative, Demographics (Enrollment), Investigator Signature, For Coulter Use Only, Demographics (General Medical History), Medical History Date, General Medical History, Prior Therapy, Prior Radiation Therapy, History of Lymphoma, Lymphoma Cell Type, Lymphoma Grade , History of Lymphoma

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

CLL Demographics and Medical History BO17072 NCT00090051 - Demographics and Medical History Chronic Lymphocytic Leukemia NCT00090051

- 15/03/2021 - 1 Formulário, 8 Grupos de itens, 28 Elementos de dados, 1 Idioma

Grupos de itens: Demographics, Serum pregnancy test, History of diseases, History of treatments, Previous treatments chemotherapy, Previous treatments radiotherapy, Surgery, Other treatment

An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 Roche BO17072 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Bipolar Affective Disorder (BipoläR) Swedish National Quality Registry - Anamnesis

- 15/03/2021 - 1 Formulário, 12 Grupos de itens, 85 Elementos de dados, 2 Idiomas

Grupos de itens: General Information, Medical History, Social Anamnesis, Affective Episodes, Self-Injurious Behavior, Treatment History, Ongoing Pharmacotherapy, Somatic Factors, Substance Use Disorders, Psychiatric comorbidity, Global Assessment of Functioning, Clinical Global Impression

Bipolar Affective Disorder (BipoläR) Swedish National Quality Registry Head of Registry: Mikael Landén Professor at the Sahlgrenska Academy, consultant at Sahlgrenska University Hospital, 411 18 Gothenburg Source: http://www.psykiatriregister.se/dokumentarkiv/bipolar S:t Göranprojekts (Making Projects) Anamnesis protocol for bipolar syndrom (version 3)

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening

- 15/03/2021 - 1 Formulário, 24 Grupos de itens, 129 Elementos de dados, 2 Idiomas

Grupos de itens: Header, Eligibility Question, Demography, Physical examination, Disease Characteristics, Metastatic Disease Site, local laboratory, Residual toxicities related to previous therapy for cancer, Residual toxicities, Cancer related current medical conditions, Medical Conditions, non-cancer related medical conditions, Medical Conditions, Prior anti-cancer therapy, Prior anti-cancer therapy - medication, Prior anti-cancer therapy - radiotherapy, Vital signs, ECOG Performance Status Scale, 12 LEAD ECG, 12-lead ECG Abnormalities, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Electronically transferred laboratory data

Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853